Cyclomydril

Manufacturer
Alcon Laboratories, Inc. | Alcon Research LLC
Effective date
2025-05-15
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
13
Source
full-release
Hydrated at
2026-05-31 21:33:27

Label at a glance#

ProductCyclomydril
Active ingredientCYCLOPENTOLATE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
Label structure12 sections

Indications and uses

For the production of mydriasis.

Dosage and administration

Instill one drop in each eye every five to ten minutes. To minimize systemic absorption, apply pressure over the nasolacrimal sac for two to three minutes following instillation. Observe infants closely for at least 30 minutes.

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

CYCLOMYDRIL® (cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution) is a mydriatic prepared as a sterile topical ophthalmic solution. The active ingredients are represented by the chemical structures:

cyclopentolate hydrochloride
cyclopentolate hydrochloride

Established Name:
Cyclopentolate Hydrochloride

Chemical Name:
2-(Dimethylamino)ethyl 1 - hydroxy-α-phenylcyclopentaneacetate hydrochloride)

Molecular Formula:
C17H25NO3 • HCl

Molecular Weight:
327.85 g/mol

phenylephrine hydrochloride
phenylephrine hydrochloride

Established Name:
Phenylephrine Hydrochloride

Chemical Name:
3-hydroxy-α[(methylamino)-methyl]-, Benzenemethanol, hydrochloride (R)-.

Molecular Formula:
C9H13NO2 • HCl

Molecular Weight:
203.67 g/mol

Each mL of CYCLOMYDRIL® (cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution) contains:
Active: cyclopentolate hydrochloride 0.2%, phenylephrine hydrochloride 1%. Preservative: benzalkonium chloride 0.01%.
Inactives: edetate disodium, boric acid, hydrochloric acid and /or sodium carbonate (to adjust pH), purified water.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Cyclopentolate hydrochloride is an anticholinergic drug and phenylephrine hydrochloride is an adrenergic drug. This combination induces mydriasis that is greater than that of either drug alone at its respective concentration. The concentrations of cyclopentolate hydrochloride and phenylephrine hydrochloride have been selected to induce mydriasis with little accompanying cycloplegia. Heavily pigmented irides may require more doses than lightly pigmented irides.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

For the production of mydriasis.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Do not use in patients with hypersensitivity to any component of this preparation.

WARNINGS

WARNINGS SECTION

FOR TOPICAL OPHTHALMIC USE ONLY. NOT FOR INJECTION. There have been reports of serious cardiovascular reactions, including ventricular arrhythmias and myocardial infarctions, in patients using higher concentrations of phenylephrine. These episodes, some fatal, have usually occurred in patients with pre-existing cardiovascular diseases. This preparation may cause central nervous system (CNS) disturbances. This is especially true in younger age groups, but may occur at any age, especially with the stronger solutions. Infants are especially prone to CNS and cardiopulmonary side effects from cyclopentolate.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

Caution should be observed when considering use of this medication in the presence of Down's syndrome due to potential increased sensitivity to anticholinergics. This product should be used with caution in patients at risk for angle closure due to the potential to precipitate acute angle closure. Because of the risk of provoking hyperthermia, use with caution in patients, especially children, who may be exposed to elevated environmental temperatures or who are febrile.  The use of phenylephrine in the eye may liberate pigment granules from the iris. Mydriatics may produce a transient elevation of intraocular pressure.

Information for Patients

INFORMATION FOR PATIENTS SECTION

Do not touch dropper tip to any surface, as this may contaminate the solution. Patient should be advised not to drive or engage in hazardous activities while pupils are dilated. Patient may experience sensitivity to light.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

There have been no long-term studies done using cyclopentolate hydrochloride and/or phenylephrine hydrochloride in animals to evaluate carcinogenic potential.

Pregnancy

PREGNANCY SECTION

Animal reproduction studies have not been conducted with cyclopentolate hydrochloride and/or phenylephrine hydrochloride. It is also not known whether cyclopentolate hydrochloride and/or phenylephrine hydrochloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. CYCLOMYDRIL® (cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution) should be given to a pregnant woman only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether these drugs are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when CYCLOMYDRIL® (cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution) is administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Use of cyclopentolate has been associated with psychotic reactions and behavioral disturbances in pediatric patients. Increased susceptibility to cyclopentolate has been reported in infants, young children, and in children with spastic paralysis or brain damage. These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place. Feeding intolerance may follow ophthalmic use of this product in infants. It is recommended that feeding be withheld after administration, and to observe infants closely for at least 30 minutes (see PRECAUTIONS).

Geriatric Use

GERIATRIC USE SECTION

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Ocular

The following ocular adverse experiences have been associated with the use of CYCLOMYDRIL® (cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution): increased intraocular pressure, burning/irritation upon instillation, photophobia, blurred vision and superficial punctate keratitis.

Nonocular

Use of cyclopentolate hydrochloride has been associated with psychotic reactions and behavioral disturbances in children. These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place. This drug produces reactions similar to those of other adrenergic and anticholinergic drugs; however, the central nervous system manifestations as noted above are most common. Other manifestations of adrenergic and anticholinergic topical ophthalmic drugs include tachycardia, hyperpyrexia, hypertension, vasodilation, urinary retention, diminished gastrointestinal motility, convulsion, bradycardia, apnea, necrotizing colitis and abdominal distention (in newborns and especially premature infants), skin rash, drowsiness, and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Severe manifestations of toxicity include coma, medullary paralysis and death. Systemic toxicity can result from topical application of sympathomimetic drugs: headache, blood pressure elevation, extrasystoles, tachycardia, syncope and cerebrovascular accidents have been reported.

OVERDOSAGE

OVERDOSAGE SECTION

Excessive dosage may produce behavioral disturbances, tachycardia, hyperpyrexia, hypertension, elevated intraocular pressure, vasodilation, urinary retention, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Pulmonary oedema or cardiac arrest may occur due to phenylephrine toxicity.  Severe intoxication is characterized by central nervous system depression, coma, circulatory and respiratory failure, and death.
Patients exhibiting signs of overdosage should receive supportive care and monitoring.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Instill one drop in each eye every five to ten minutes. To minimize systemic absorption, apply pressure over the nasolacrimal sac for two to three minutes following instillation. Observe infants closely for at least 30 minutes.

HOW SUPPLIED

HOW SUPPLIED SECTION

CYCLOMYDRIL® (cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution) is supplied as a sterile solution in 2 mL and 5 mL, in plastic DROP-TAINER® dispensers.

2 mL           NDC 0065-0359-02

5 mL           NDC 0065-0359-05

Storage: Store at 8°C to 25°C (46°F - 77°F)

SPL UNCLASSIFIED SECTION


Distributed by:
ALCON LABORATORIES, INC.
6201 South Freeway
Fort Worth, Texas 76134-2099

© 2025 Alcon Inc.


Revised: May 2025.

300065206-1223

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0065-0359-05

Alcon
Cyclomydril®
(cyclopentolate
hydrochloride,
phenylephrine
hydrochloride
ophthalmic
solution)

5 mL Sterile

Rx Only

Sterile Ophthalmic Solution

USUAL DOSAGE: Instill one drop
in each eye every five to ten
minutes. Read enclosed insert.

FOR TOPICAL OPHTHALMIC USE
ONLY

WARNING: Do not touch
dropper tip to any surface as
this may contaminate the
solution.

INGREDIENTS: Each mL
contains: Active:
cyclopentolate hydrochloride
0.2%, phenylephrine
hydrochloride 1%.
Preservative: benzalkonium
chloride 0.01%. Inactives:
edetate disodium, boric acid,
hydrochloric acid and/or
sodium carbonate (to adjust
pH), purified water.

STORAGE: Store at 8°-25° C
(46° to 77° F).

Alcon

ALCON LABORATORIES, INC.
Fort Worth, Texas 76134 USA
Printed in USA

SN:
LOT:
EXP.:
GTIN: 00300650359054


300048632-0821

Carton Label
Carton Label

NDC 0065-0359-05

Alcon
Cyclomydril®
(cyclopentolate
hydrochloride,
phenylephrine
hydrochloride
ophthalmic
solution)

Sterile 5 mL

Rx Only

INGREDIENTS: Each mL contains: Actives: cyclopentolate
hydrochloride 0.2%, phenylephrine hydrochloride 1%.
Preservative: benzalkonium chloride 0.01%. Inactives:
edetate disodium, boric acid, hydrochloric acid and/or
sodium carbonate (to adjust pH), purified water.

WARNING: Do not touch dropper tip to any surface as this
may contaminate the solution.

USUAL DOSAGE: Instill one drop in each eye every five to
ten minutes. Read enclosed insert.

STORAGE: Store at 8°-25° C (46° to 77° F).

Printed in USA

ALCON LABORATORIES, INC.
Fort Worth, Texas 76134 USA

LOT:

EXP.:

300048631-0821

label
label

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
1298360Cyclomydril 0.2 % / 1 % Ophthalmic SolutionPSN13
1298068cyclopentolate HCl 0.2 % / phenylephrine HCl 1 % Ophthalmic SolutionPSN13
1298360cyclopentolate hydrochloride 2 MG/ML / phenylephrine hydrochloride 10 MG/ML Ophthalmic Solution [Cyclomydril]SBD13
1298068cyclopentolate hydrochloride 2 MG/ML / phenylephrine hydrochloride 10 MG/ML Ophthalmic SolutionSCD13
1298360Cyclomydril (cyclopentolate hydrochloride 0.2 % / phenylephrine hydrochloride 1 % ) Ophthalmic DropsSY13
1298068cyclopentolate hydrochloride 0.2 % / phenylephrine hydrochloride 1 % Ophthalmic DropsSY13

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
PHENYLEPHRINE Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
e4e263da-1c53-440f-bb80-b7a575843b5aProduct name120260313
d2168cac-a261-415a-9c78-3522859fa720Product name320251124
05a8cdd1-eeb8-409e-b938-0778225eca7dProduct name420250221
e5b5c132-b15d-435b-9faa-2f74e5cadcf9Product name820250220
f489e8f3-5c9e-4818-b539-a73587edcfc7Product name220240229
0f7ae452-206d-4fc4-868d-56fc47074084Product name120231011
b5abe2e3-39a1-43eb-9bff-f3c1653fe3dfProduct name220190930
da26936b-2875-4173-812f-99a1f7074052Product name120151215
e0b6c8be-f2bd-9f86-a9fc-3ed56ffaa814Product name320150910
42f3c020-f1b3-89bc-7bdc-e1f10e680485Product name120140508
e949165d-714d-e548-2b76-0cb5def16f30Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0065-0359-02Cyclomydril2 mL in 1 BOTTLE, PLASTICSOLUTION/ DROPS213
0065-0359-05Cyclomydril5 mL in 1 BOTTLE, PLASTICSOLUTION/ DROPS513

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
0065-0359CYCLOMYDRIL (CYCLOPENTOLATE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE) SOLUTION/ DROPS [ALCON LABORATORIES, INC.]13Current NDC, Legacy NDC, 2 package rows20250519_8268b70f-3f10-48dd-bb24-baaeb27a1325.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
0065-0359-02ML - Milliliter0065-03593047c504-b1b6-4875-9d0c-cef8add6b84612012-07-24
0065-0359-05ML - Milliliter0065-0359ef866a71-65f9-4955-9af7-572eb6a459db12012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
CYCLOPENTOLATE HYDROCHLORIDEACTIVE INGREDIENT736I6971TE5
PHENYLEPHRINE HYDROCHLORIDEACTIVE INGREDIENT04JA59TNSJ5
CYCLOPENTOLATEACTIVE MOIETYI76F4SHP7J5
PHENYLEPHRINEACTIVE MOIETY1WS297W6MV5
BENZALKONIUM CHLORIDEINACTIVE INGREDIENTF5UM2KM3W75
BORIC ACIDINACTIVE INGREDIENTR57ZHV85D45
EDETATE DISODIUMINACTIVE INGREDIENT7FLD91C86K5
HYDROCHLORIC ACIDINACTIVE INGREDIENTQTT17582CB5
SODIUM CARBONATEINACTIVE INGREDIENT45P3261C7T5
WATERINACTIVE INGREDIENT059QF0KO0R5

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 12 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0065-03590065-0359-02, 0065-0359-05

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 8 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 1 · 15 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
SODIUM CARBONATESODIUM CARBONATE45P3261C7TSOLUTION / OPHTHALMIC0.01 %w/vExact identifier — unii+route
3 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSOLUTION/ DROPS / OPHTHALMIC0.13 %w/vExact identifier — unii+route+dosage form
3 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSOLUTION/ DROPS / OPHTHALMIC0.13 %w/vExact identifier — unii+route+dosage form
3 equally ranked IID candidates
EDETATE DISODIUMEDETATE DISODIUM7FLD91C86KSOLUTION/ DROPS / OPHTHALMIC0.13 %w/vExact identifier — unii+route+dosage form
3 equally ranked IID candidates
BORIC ACIDBORIC ACIDR57ZHV85D4SOLUTION/ DROPS / OPHTHALMIC48 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
BORIC ACIDBORIC ACIDR57ZHV85D4SOLUTION/ DROPS / OPHTHALMIC48 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
SODIUM CARBONATESODIUM CARBONATE45P3261C7TSOLUTION / OPHTHALMIC0.01 %w/vExact identifier — unii+route
3 equally ranked IID candidates
BENZALKONIUM CHLORIDEBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION/ DROPS / OPHTHALMIC1 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
BENZALKONIUM CHLORIDEBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION/ DROPS / OPHTHALMIC1 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
BORIC ACIDBORIC ACIDR57ZHV85D4SOLUTION/ DROPS / OPHTHALMIC48 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBSOLUTION/ DROPS / OPHTHALMICADJ PHExact identifier — unii+route+dosage form
3 equally ranked IID candidates
BENZALKONIUM CHLORIDEBENZALKONIUM CHLORIDEF5UM2KM3W7SOLUTION/ DROPS / OPHTHALMIC1 mgExact identifier — unii+route+dosage form
3 equally ranked IID candidates
SODIUM CARBONATESODIUM CARBONATE45P3261C7TSOLUTION / OPHTHALMIC0.01 %w/vExact identifier — unii+route
3 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBSOLUTION/ DROPS / OPHTHALMICADJ PHExact identifier — unii+route+dosage form
3 equally ranked IID candidates
HYDROCHLORIC ACIDHYDROCHLORIC ACIDQTT17582CBSOLUTION/ DROPS / OPHTHALMICADJ PHExact identifier — unii+route+dosage form
3 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A084300-001CYCLOMYDRILCYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE0.2%;1%SOLUTION/DROPS / OPHTHALMICRLD, RS, Approved before 1982

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRLD, RS, Approved before 1982c2088c7a36db…
2026-09-14 22:38:342026-08A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRLD, RS, Approved before 198284e616aacf4f…
2026-08-18 06:07:402026-07A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRLD, RS, Approved before 1982caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRLD, RS, Approved before 1982011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRLD, RS, Approved before 198231067a03dcf5…
2025-08-23 18:47 UTC2025-08A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRLD, RS, Approved before 19826a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 1982fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 1982b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 198203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 19822680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 19825bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 1982d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 1982d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 198279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 1982301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 19821e350fbaab3a…
2024-05-31 18:47 UTC2024-05A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 19828072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 19825c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 19825d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 19824b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 198274a2ff9319b5…
2022-03-09 01:35 UTC2022-03A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 1982bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 1982782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 198287673890dc5c…
2021-03-12 10:30 UTC2021-03A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 19825aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 19828869cabd3fbd…
2020-11-12 02:37 UTC2020-11A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 1982c0c555d07b60…
2019-12-14 00:12 UTC2019-12A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 19823f01610625f2…
2019-09-15 20:21 UTC2019-09A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 1982b00525d2431f…
2019-07-19 19:46 UTC2019-07A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 1982ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 19826a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 19821c564ffb4f44…
2023-12-20 04:57 UTC2023-12A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 1982ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 1982a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 19829b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 1982a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 19823f0d92c62455…
2023-05-13 08:27 UTC2023-05A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 1982053a50430f4f…
2023-01-26 05:58 UTC2023-01A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 19823bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A084300-001CYCLOMYDRIL0.2%;1%SOLUTION/DROPS / OPHTHALMICRS, Approved before 19823a93d1ddd44b…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
CyclomydrilCYCLOPENTOLATE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDEAlcon Laboratories, Inc.8268b70f-3f10-48dd-bb24-baaeb27a13252025-05-15Warnings, Adverse reactionsExact identifier
ndc (package): 0065-0359-05
ndc (package): 0065-0359-02
ndc (product): 0065-0359
ndc11 (package): 00065035902
ndc11 (package): 00065035905
spl id: 3c5dad7d-4db2-4615-92cb-01ea4d769adf
spl set id: 8268b70f-3f10-48dd-bb24-baaeb27a1325

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.